Stem definition | Drug id | CAS RN |
---|---|---|
serotonin (5-HT1) receptor agonists, sumatriptan derivatives | 2543 | 103628-46-2 |
Dose | Unit | Route |
---|---|---|
20 | mg | N |
50 | mg | O |
6 | mg | P |
25 | mg | R |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 21.40 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 22 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.68 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 14 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 1.70 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 19 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.83 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 1.70 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Dec. 28, 1992 | FDA | GLAXOSMITHKLINE |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Product physical issue | 4103.62 | 11.46 | 911 | 45263 | 3671 | 56242222 |
Migraine | 1094.57 | 11.46 | 751 | 45423 | 86046 | 56159847 |
Product dose omission issue | 1052.84 | 11.46 | 1051 | 45123 | 203702 | 56042191 |
Application site erythema | 566.64 | 11.46 | 192 | 45982 | 4408 | 56241485 |
Product quality issue | 507.34 | 11.46 | 319 | 45855 | 31417 | 56214476 |
Application site burn | 379.94 | 11.46 | 95 | 46079 | 692 | 56245201 |
Device deployment issue | 334.31 | 11.46 | 122 | 46052 | 3502 | 56242391 |
Application site pain | 328.61 | 11.46 | 123 | 46051 | 3797 | 56242096 |
Device malfunction | 327.09 | 11.46 | 189 | 45985 | 15947 | 56229946 |
Application site discolouration | 266.63 | 11.46 | 71 | 46103 | 681 | 56245212 |
Device issue | 256.73 | 11.46 | 179 | 45995 | 20927 | 56224966 |
Application site paraesthesia | 193.47 | 11.46 | 36 | 46138 | 39 | 56245854 |
Headache | 146.92 | 11.46 | 869 | 45305 | 558175 | 55687718 |
Rheumatoid arthritis | 145.60 | 11.46 | 66 | 46108 | 382538 | 55863355 |
Accidental exposure to product | 145.51 | 11.46 | 137 | 46037 | 24510 | 56221383 |
Application site urticaria | 138.40 | 11.46 | 34 | 46140 | 228 | 56245665 |
Application site rash | 132.97 | 11.46 | 56 | 46118 | 2367 | 56243526 |
Medication overuse headache | 125.51 | 11.46 | 39 | 46135 | 672 | 56245221 |
Application site irritation | 124.61 | 11.46 | 48 | 46126 | 1604 | 56244289 |
Colitis ischaemic | 117.21 | 11.46 | 83 | 46091 | 9937 | 56235956 |
Application site warmth | 115.17 | 11.46 | 27 | 46147 | 144 | 56245749 |
Application site pruritus | 111.53 | 11.46 | 57 | 46117 | 3762 | 56242131 |
Arteriospasm coronary | 96.66 | 11.46 | 51 | 46123 | 3596 | 56242297 |
Anxiety | 95.16 | 11.46 | 361 | 45813 | 192811 | 56053082 |
Glossodynia | 92.52 | 11.46 | 9 | 46165 | 152449 | 56093444 |
Needle issue | 89.96 | 11.46 | 67 | 46107 | 8671 | 56237222 |
Death | 89.43 | 11.46 | 89 | 46085 | 341337 | 55904556 |
Injection site pain | 86.39 | 11.46 | 251 | 45923 | 116867 | 56129026 |
Application site scar | 82.89 | 11.46 | 22 | 46152 | 208 | 56245685 |
Systemic lupus erythematosus | 82.11 | 11.46 | 23 | 46151 | 180055 | 56065838 |
Application site vesicles | 79.79 | 11.46 | 33 | 46141 | 1332 | 56244561 |
Paraesthesia | 77.13 | 11.46 | 259 | 45915 | 130255 | 56115638 |
Arthropathy | 76.91 | 11.46 | 34 | 46140 | 200241 | 56045652 |
Injection site haemorrhage | 75.29 | 11.46 | 92 | 46082 | 22109 | 56223784 |
Throat tightness | 73.00 | 11.46 | 91 | 46083 | 22316 | 56223577 |
Wound | 72.76 | 11.46 | 13 | 46161 | 138791 | 56107102 |
Application site swelling | 71.66 | 11.46 | 24 | 46150 | 530 | 56245363 |
Contraindicated product administered | 70.93 | 11.46 | 32 | 46142 | 186254 | 56059639 |
Product substitution issue | 69.17 | 11.46 | 72 | 46102 | 14527 | 56231366 |
Infusion related reaction | 69.10 | 11.46 | 43 | 46131 | 208888 | 56037005 |
Reversible cerebral vasoconstriction syndrome | 68.03 | 11.46 | 35 | 46139 | 2342 | 56243551 |
IIIrd nerve paresis | 67.60 | 11.46 | 17 | 46157 | 127 | 56245766 |
Wrong technique in product usage process | 67.36 | 11.46 | 148 | 46026 | 58020 | 56187873 |
Device power source issue | 65.26 | 11.46 | 22 | 46152 | 496 | 56245397 |
Muscle twitching | 64.53 | 11.46 | 73 | 46101 | 16169 | 56229724 |
Treatment failure | 63.73 | 11.46 | 30 | 46144 | 170362 | 56075531 |
Drug ineffective | 63.69 | 11.46 | 1081 | 45093 | 917908 | 55327985 |
Product complaint | 63.03 | 11.46 | 62 | 46112 | 11698 | 56234195 |
Depression | 62.64 | 11.46 | 303 | 45871 | 179814 | 56066079 |
Cerebral vasoconstriction | 62.02 | 11.46 | 26 | 46148 | 1086 | 56244807 |
Acute kidney injury | 61.57 | 11.46 | 64 | 46110 | 240699 | 56005194 |
Serotonin syndrome | 59.69 | 11.46 | 90 | 46084 | 26400 | 56219493 |
Coronary artery dissection | 56.56 | 11.46 | 22 | 46152 | 755 | 56245138 |
Application site exfoliation | 56.28 | 11.46 | 18 | 46156 | 342 | 56245551 |
Anaemia | 55.94 | 11.46 | 83 | 46091 | 267428 | 55978465 |
Product leakage | 55.25 | 11.46 | 21 | 46153 | 676 | 56245217 |
Endometriosis | 55.11 | 11.46 | 39 | 46135 | 4663 | 56241230 |
Application site dryness | 55.05 | 11.46 | 15 | 46159 | 158 | 56245735 |
Concussion | 54.81 | 11.46 | 49 | 46125 | 8197 | 56237696 |
Chest discomfort | 53.86 | 11.46 | 191 | 45983 | 98666 | 56147227 |
Dizziness | 53.78 | 11.46 | 507 | 45667 | 375633 | 55870260 |
Cholecystitis chronic | 53.38 | 11.46 | 52 | 46122 | 9696 | 56236197 |
Abdominal discomfort | 52.37 | 11.46 | 92 | 46082 | 277182 | 55968711 |
Joint swelling | 52.20 | 11.46 | 99 | 46075 | 289701 | 55956192 |
Application site reaction | 51.98 | 11.46 | 20 | 46154 | 666 | 56245227 |
Lower respiratory tract infection | 51.67 | 11.46 | 15 | 46159 | 114779 | 56131114 |
Pituitary tumour benign | 51.20 | 11.46 | 27 | 46147 | 1901 | 56243992 |
Post-traumatic neck syndrome | 50.55 | 11.46 | 27 | 46147 | 1951 | 56243942 |
Injection site bruising | 50.36 | 11.46 | 103 | 46071 | 38418 | 56207475 |
Emotional distress | 49.29 | 11.46 | 88 | 46086 | 29675 | 56216218 |
Application site scab | 48.98 | 11.46 | 14 | 46160 | 178 | 56245715 |
Somnambulism | 47.90 | 11.46 | 37 | 46137 | 5055 | 56240838 |
Renal infarct | 47.37 | 11.46 | 23 | 46151 | 1359 | 56244534 |
Hostility | 46.81 | 11.46 | 25 | 46149 | 1806 | 56244087 |
Device leakage | 46.63 | 11.46 | 40 | 46134 | 6335 | 56239558 |
Drug specific antibody | 46.53 | 11.46 | 26 | 46148 | 2054 | 56243839 |
Alopecia | 46.34 | 11.46 | 108 | 46066 | 293350 | 55952543 |
Swelling | 45.77 | 11.46 | 79 | 46095 | 239692 | 56006201 |
Incorrect dose administered by device | 45.65 | 11.46 | 32 | 46142 | 3768 | 56242125 |
Libido increased | 45.47 | 11.46 | 22 | 46152 | 1290 | 56244603 |
Febrile neutropenia | 45.34 | 11.46 | 15 | 46159 | 105530 | 56140363 |
Cardiac failure | 44.53 | 11.46 | 7 | 46167 | 82086 | 56163807 |
Soft tissue injury | 44.19 | 11.46 | 23 | 46151 | 1576 | 56244317 |
Neutropenia | 42.76 | 11.46 | 40 | 46134 | 158127 | 56087766 |
Incorrect route of product administration | 41.84 | 11.46 | 68 | 46106 | 21261 | 56224632 |
Expired product administered | 40.67 | 11.46 | 35 | 46139 | 5567 | 56240326 |
Off label use | 40.36 | 11.46 | 279 | 45895 | 555901 | 55689992 |
Hepatic enzyme increased | 40.03 | 11.46 | 49 | 46125 | 171335 | 56074558 |
Application site inflammation | 39.55 | 11.46 | 14 | 46160 | 367 | 56245526 |
Nightmare | 39.09 | 11.46 | 58 | 46116 | 16768 | 56229125 |
Disease progression | 38.57 | 11.46 | 19 | 46155 | 105154 | 56140739 |
Application site bruise | 38.57 | 11.46 | 13 | 46161 | 293 | 56245600 |
Tension headache | 38.54 | 11.46 | 26 | 46148 | 2877 | 56243016 |
Sternal fracture | 38.44 | 11.46 | 23 | 46151 | 2067 | 56243826 |
Suicidal ideation | 38.05 | 11.46 | 119 | 46055 | 57623 | 56188270 |
Synovitis | 37.79 | 11.46 | 46 | 46128 | 161259 | 56084634 |
Hot flush | 37.20 | 11.46 | 103 | 46071 | 46623 | 56199270 |
Feeling abnormal | 36.93 | 11.46 | 211 | 45963 | 133391 | 56112502 |
Nausea | 36.57 | 11.46 | 851 | 45323 | 763327 | 55482566 |
Angle closure glaucoma | 36.05 | 11.46 | 22 | 46152 | 2049 | 56243844 |
Clonus | 35.94 | 11.46 | 29 | 46145 | 4220 | 56241673 |
Hypotension | 35.05 | 11.46 | 98 | 46076 | 250410 | 55995483 |
Peripheral swelling | 34.98 | 11.46 | 89 | 46085 | 234637 | 56011256 |
Infection | 34.63 | 11.46 | 70 | 46104 | 200136 | 56045757 |
Secondary adrenocortical insufficiency | 34.20 | 11.46 | 18 | 46156 | 1262 | 56244631 |
Pre-existing condition improved | 34.17 | 11.46 | 36 | 46138 | 7362 | 56238531 |
Product use issue | 33.95 | 11.46 | 63 | 46111 | 185978 | 56059915 |
Atrial fibrillation | 33.83 | 11.46 | 24 | 46150 | 108873 | 56137020 |
Pneumonia | 33.70 | 11.46 | 196 | 45978 | 406902 | 55838991 |
Hypoaesthesia | 33.11 | 11.46 | 214 | 45960 | 141277 | 56104616 |
General physical health deterioration | 32.44 | 11.46 | 56 | 46118 | 169954 | 56075939 |
Dysgeusia | 32.38 | 11.46 | 90 | 46084 | 40825 | 56205068 |
Muscle tightness | 32.12 | 11.46 | 42 | 46132 | 10794 | 56235099 |
Renal impairment | 32.08 | 11.46 | 13 | 46161 | 80700 | 56165193 |
Therapeutic response unexpected | 31.63 | 11.46 | 53 | 46121 | 16991 | 56228902 |
Impaired healing | 31.37 | 11.46 | 16 | 46158 | 86825 | 56159068 |
Chest pain | 31.24 | 11.46 | 264 | 45910 | 189533 | 56056360 |
Pancytopenia | 31.08 | 11.46 | 17 | 46157 | 88698 | 56157195 |
Haemoglobin decreased | 30.63 | 11.46 | 39 | 46135 | 134098 | 56111795 |
Diarrhoea | 29.84 | 11.46 | 358 | 45816 | 638149 | 55607744 |
Hyponatraemia | 28.59 | 11.46 | 25 | 46149 | 102114 | 56143779 |
Interstitial lung disease | 28.50 | 11.46 | 6 | 46168 | 57057 | 56188836 |
Device defective | 28.48 | 11.46 | 17 | 46157 | 1521 | 56244372 |
Hyperkalaemia | 28.36 | 11.46 | 4 | 46170 | 50861 | 56195032 |
Application site discomfort | 28.18 | 11.46 | 11 | 46163 | 381 | 56245512 |
Drug-disease interaction | 28.13 | 11.46 | 11 | 46163 | 383 | 56245510 |
Renal tubular acidosis | 27.91 | 11.46 | 17 | 46157 | 1578 | 56244315 |
Application site erosion | 27.80 | 11.46 | 9 | 46165 | 178 | 56245715 |
Stomatitis | 27.71 | 11.46 | 35 | 46139 | 120775 | 56125118 |
Plasma cell myeloma | 27.64 | 11.46 | 3 | 46171 | 46643 | 56199250 |
Platelet count decreased | 27.47 | 11.46 | 28 | 46146 | 106355 | 56139538 |
Transient global amnesia | 27.29 | 11.46 | 12 | 46162 | 564 | 56245329 |
Hyperprolactinaemia | 26.83 | 11.46 | 23 | 46151 | 3638 | 56242255 |
Pharyngeal swelling | 26.64 | 11.46 | 27 | 46147 | 5279 | 56240614 |
Cluster headache | 26.31 | 11.46 | 12 | 46162 | 615 | 56245278 |
Poor quality sleep | 26.25 | 11.46 | 50 | 46124 | 17705 | 56228188 |
Photophobia | 25.99 | 11.46 | 47 | 46127 | 16003 | 56229890 |
Vasospasm | 25.97 | 11.46 | 12 | 46162 | 634 | 56245259 |
Malignant neoplasm progression | 25.93 | 11.46 | 14 | 46160 | 73573 | 56172320 |
Migraine without aura | 25.77 | 11.46 | 10 | 46164 | 341 | 56245552 |
Rash | 24.72 | 11.46 | 272 | 45902 | 492775 | 55753118 |
Palpitations | 24.70 | 11.46 | 153 | 46021 | 99519 | 56146374 |
Somnolence | 24.64 | 11.46 | 223 | 45951 | 163190 | 56082703 |
Gastrointestinal haemorrhage | 24.57 | 11.46 | 16 | 46158 | 75935 | 56169958 |
Blood creatinine increased | 24.48 | 11.46 | 18 | 46156 | 80173 | 56165720 |
Pleural effusion | 23.82 | 11.46 | 21 | 46153 | 85459 | 56160434 |
Eyelid ptosis | 23.71 | 11.46 | 28 | 46146 | 6491 | 56239402 |
Injection site laceration | 23.68 | 11.46 | 7 | 46167 | 101 | 56245792 |
Drug hypersensitivity | 23.51 | 11.46 | 336 | 45838 | 274869 | 55971024 |
Tremor | 23.51 | 11.46 | 175 | 45999 | 120914 | 56124979 |
Narcolepsy | 23.03 | 11.46 | 14 | 46160 | 1295 | 56244598 |
Middle insomnia | 22.97 | 11.46 | 36 | 46138 | 10914 | 56234979 |
Oxygen saturation decreased | 22.55 | 11.46 | 19 | 46155 | 79048 | 56166845 |
Sepsis | 22.41 | 11.46 | 51 | 46123 | 139789 | 56106104 |
Application site papules | 21.95 | 11.46 | 6 | 46168 | 64 | 56245829 |
Personality disorder | 21.83 | 11.46 | 24 | 46150 | 5149 | 56240744 |
Vasoconstriction | 21.67 | 11.46 | 10 | 46164 | 527 | 56245366 |
Hip arthroplasty | 21.62 | 11.46 | 3 | 46171 | 38620 | 56207273 |
Vision blurred | 21.61 | 11.46 | 129 | 46045 | 82814 | 56163079 |
Underdose | 21.57 | 11.46 | 55 | 46119 | 23702 | 56222191 |
Irritability | 21.38 | 11.46 | 63 | 46111 | 29525 | 56216368 |
Blood testosterone increased | 20.88 | 11.46 | 7 | 46167 | 155 | 56245738 |
Septic shock | 20.81 | 11.46 | 12 | 46162 | 60823 | 56185070 |
Post-traumatic stress disorder | 20.81 | 11.46 | 22 | 46152 | 4516 | 56241377 |
Injection site injury | 20.80 | 11.46 | 10 | 46164 | 578 | 56245315 |
Muscle spasms | 20.47 | 11.46 | 187 | 45987 | 137184 | 56108709 |
Gastrooesophageal reflux disease | 20.12 | 11.46 | 127 | 46047 | 83130 | 56162763 |
Dependence | 19.86 | 11.46 | 15 | 46159 | 1982 | 56243911 |
Phonophobia | 19.85 | 11.46 | 8 | 46166 | 302 | 56245591 |
Pyrexia | 19.81 | 11.46 | 234 | 45940 | 418539 | 55827354 |
Neck pain | 19.55 | 11.46 | 101 | 46073 | 61454 | 56184439 |
Migraine with aura | 19.53 | 11.46 | 16 | 46158 | 2378 | 56243515 |
Cardiac failure congestive | 19.51 | 11.46 | 26 | 46148 | 87694 | 56158199 |
Basilar migraine | 19.47 | 11.46 | 5 | 46169 | 41 | 56245852 |
Product adhesion issue | 19.27 | 11.46 | 21 | 46153 | 4462 | 56241431 |
Neonatal respiratory distress | 19.02 | 11.46 | 8 | 46166 | 337 | 56245556 |
Large intestinal ulcer haemorrhage | 18.96 | 11.46 | 6 | 46168 | 110 | 56245783 |
Renal failure | 18.78 | 11.46 | 39 | 46135 | 110461 | 56135432 |
Biliary dyskinesia | 18.58 | 11.46 | 16 | 46158 | 2547 | 56243346 |
Spleen congestion | 18.57 | 11.46 | 6 | 46168 | 118 | 56245775 |
Sunburn | 18.55 | 11.46 | 16 | 46158 | 2552 | 56243341 |
Cerebral venous thrombosis | 18.21 | 11.46 | 14 | 46160 | 1899 | 56243994 |
Paraesthesia oral | 18.13 | 11.46 | 38 | 46136 | 14411 | 56231482 |
Red blood cell sedimentation rate increased | 17.98 | 11.46 | 4 | 46170 | 36619 | 56209274 |
Thrombocytopenia | 17.79 | 11.46 | 55 | 46119 | 136169 | 56109724 |
Depressive symptom | 17.74 | 11.46 | 18 | 46156 | 3523 | 56242370 |
Osteonecrosis of jaw | 17.74 | 11.46 | 3 | 46171 | 33355 | 56212538 |
Incorrect product administration duration | 17.70 | 11.46 | 31 | 46143 | 10295 | 56235598 |
Device use error | 17.51 | 11.46 | 22 | 46152 | 5434 | 56240459 |
Decreased appetite | 17.33 | 11.46 | 107 | 46067 | 219124 | 56026769 |
Complement factor C4 decreased | 17.32 | 11.46 | 7 | 46167 | 266 | 56245627 |
Discomfort | 17.29 | 11.46 | 59 | 46115 | 141702 | 56104191 |
Multiple organ dysfunction syndrome | 17.23 | 11.46 | 11 | 46163 | 52759 | 56193134 |
Blister | 17.21 | 11.46 | 40 | 46134 | 108847 | 56137046 |
Hyperhidrosis | 17.15 | 11.46 | 134 | 46040 | 93954 | 56151939 |
Lactic acidosis | 17.08 | 11.46 | 4 | 46170 | 35342 | 56210551 |
Complement factor C3 decreased | 16.82 | 11.46 | 7 | 46167 | 287 | 56245606 |
Memory impairment | 16.74 | 11.46 | 125 | 46049 | 86432 | 56159461 |
Cough | 16.59 | 11.46 | 135 | 46039 | 259826 | 55986067 |
Seizure | 16.50 | 11.46 | 166 | 46008 | 124953 | 56120940 |
Application site dermatitis | 16.41 | 11.46 | 6 | 46168 | 173 | 56245720 |
Subclavian artery thrombosis | 16.41 | 11.46 | 6 | 46168 | 173 | 56245720 |
Meningoradiculitis | 16.38 | 11.46 | 5 | 46169 | 81 | 56245812 |
Sleep talking | 16.33 | 11.46 | 10 | 46164 | 937 | 56244956 |
Drug dependence | 16.30 | 11.46 | 48 | 46126 | 22485 | 56223408 |
Knee arthroplasty | 16.21 | 11.46 | 8 | 46166 | 44251 | 56201642 |
International normalised ratio increased | 16.07 | 11.46 | 8 | 46166 | 44033 | 56201860 |
Superior sagittal sinus thrombosis | 16.03 | 11.46 | 9 | 46165 | 718 | 56245175 |
Bipolar disorder | 16.01 | 11.46 | 25 | 46149 | 7555 | 56238338 |
Major depression | 16.00 | 11.46 | 25 | 46149 | 7559 | 56238334 |
Hyperacusis | 15.97 | 11.46 | 13 | 46161 | 1915 | 56243978 |
Transverse sinus thrombosis | 15.81 | 11.46 | 8 | 46166 | 517 | 56245376 |
Gastrointestinal disorder | 15.80 | 11.46 | 44 | 46130 | 112658 | 56133235 |
Maternal exposure during pregnancy | 15.78 | 11.46 | 91 | 46083 | 189462 | 56056431 |
Injury | 15.53 | 11.46 | 93 | 46081 | 59758 | 56186135 |
Burning sensation | 15.53 | 11.46 | 80 | 46094 | 48616 | 56197277 |
Multiple sclerosis | 15.36 | 11.46 | 54 | 46120 | 27748 | 56218145 |
Hyperreflexia | 15.02 | 11.46 | 20 | 46154 | 5230 | 56240663 |
Injury associated with device | 15.01 | 11.46 | 16 | 46158 | 3317 | 56242576 |
Lichen planus | 14.78 | 11.46 | 13 | 46161 | 2129 | 56243764 |
Cerebral venous sinus thrombosis | 14.75 | 11.46 | 12 | 46162 | 1766 | 56244127 |
Liver injury | 14.68 | 11.46 | 8 | 46166 | 41840 | 56204053 |
Peripheral nerve injury | 14.59 | 11.46 | 7 | 46167 | 403 | 56245490 |
Gallbladder disorder | 14.58 | 11.46 | 39 | 46135 | 17295 | 56228598 |
Rash maculo-papular | 14.51 | 11.46 | 3 | 46171 | 28904 | 56216989 |
Multiple sclerosis relapse | 14.48 | 11.46 | 74 | 46100 | 44829 | 56201064 |
Nipple pain | 14.39 | 11.46 | 6 | 46168 | 247 | 56245646 |
Drug effect less than expected | 14.32 | 11.46 | 9 | 46165 | 883 | 56245010 |
Trismus | 14.15 | 11.46 | 16 | 46158 | 3542 | 56242351 |
Bone marrow failure | 14.07 | 11.46 | 3 | 46171 | 28283 | 56217610 |
Teratogenicity | 14.04 | 11.46 | 6 | 46168 | 263 | 56245630 |
Pancreatic failure | 14.02 | 11.46 | 9 | 46165 | 916 | 56244977 |
Withdrawal syndrome | 14.00 | 11.46 | 40 | 46134 | 18422 | 56227471 |
Potassium wasting nephropathy | 13.91 | 11.46 | 4 | 46170 | 52 | 56245841 |
Inflammation | 13.86 | 11.46 | 22 | 46152 | 69049 | 56176844 |
Ischaemic cerebral infarction | 13.83 | 11.46 | 10 | 46164 | 1236 | 56244657 |
Burns third degree | 13.75 | 11.46 | 6 | 46168 | 277 | 56245616 |
Sensory disturbance | 13.49 | 11.46 | 31 | 46143 | 12512 | 56233381 |
Gallbladder injury | 13.45 | 11.46 | 10 | 46164 | 1290 | 56244603 |
Therapeutic response shortened | 13.35 | 11.46 | 26 | 46148 | 9360 | 56236533 |
Slow speech | 13.27 | 11.46 | 10 | 46164 | 1317 | 56244576 |
Pneumonia aspiration | 13.24 | 11.46 | 5 | 46169 | 32406 | 56213487 |
Post viral fatigue syndrome | 13.20 | 11.46 | 6 | 46168 | 305 | 56245588 |
Premature delivery | 13.20 | 11.46 | 3 | 46171 | 27057 | 56218836 |
Deep vein thrombosis | 13.13 | 11.46 | 108 | 46066 | 76869 | 56169024 |
Cholestasis | 13.09 | 11.46 | 3 | 46171 | 26910 | 56218983 |
Hepatic function abnormal | 13.04 | 11.46 | 6 | 46168 | 34552 | 56211341 |
Neoplasm progression | 12.97 | 11.46 | 5 | 46169 | 32011 | 56213882 |
Meningitis aseptic | 12.96 | 11.46 | 17 | 46157 | 4382 | 56241511 |
Influenza like illness | 12.90 | 11.46 | 90 | 46084 | 60898 | 56184995 |
Toxicity to various agents | 12.82 | 11.46 | 120 | 46054 | 224444 | 56021449 |
Cardio-respiratory arrest | 12.71 | 11.46 | 16 | 46158 | 55305 | 56190588 |
Granulocyte count increased | 12.41 | 11.46 | 7 | 46167 | 563 | 56245330 |
Hepatotoxicity | 12.40 | 11.46 | 5 | 46169 | 31148 | 56214745 |
Pharyngeal oedema | 12.31 | 11.46 | 31 | 46143 | 13254 | 56232639 |
Nasal discomfort | 12.22 | 11.46 | 16 | 46158 | 4116 | 56241777 |
Melaena | 12.18 | 11.46 | 4 | 46170 | 28286 | 56217607 |
Alanine aminotransferase increased | 12.09 | 11.46 | 38 | 46136 | 93624 | 56152269 |
Chemical burn | 12.07 | 11.46 | 6 | 46168 | 373 | 56245520 |
Swollen tongue | 11.98 | 11.46 | 53 | 46121 | 30271 | 56215622 |
Ovarian neoplasm | 11.97 | 11.46 | 8 | 46166 | 872 | 56245021 |
Blood HIV RNA increased | 11.95 | 11.46 | 7 | 46167 | 605 | 56245288 |
Product packaging quantity issue | 11.81 | 11.46 | 9 | 46165 | 1205 | 56244688 |
Ill-defined disorder | 11.80 | 11.46 | 24 | 46150 | 68519 | 56177374 |
Flushing | 11.77 | 11.46 | 98 | 46076 | 70002 | 56175891 |
Therapeutic product effect decreased | 11.74 | 11.46 | 86 | 46088 | 169366 | 56076527 |
Oedema | 11.47 | 11.46 | 32 | 46142 | 81888 | 56164005 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Product physical issue | 983.18 | 17.99 | 199 | 7278 | 2056 | 31687811 |
Migraine | 288.91 | 17.99 | 113 | 7364 | 14067 | 31675800 |
Product dose omission issue | 237.32 | 17.99 | 197 | 7280 | 105389 | 31584478 |
Product quality issue | 123.61 | 17.99 | 65 | 7412 | 16046 | 31673821 |
Headache | 98.63 | 17.99 | 164 | 7313 | 183488 | 31506379 |
Device deployment issue | 95.73 | 17.99 | 18 | 7459 | 120 | 31689747 |
Arteriospasm coronary | 69.39 | 17.99 | 26 | 7451 | 2865 | 31687002 |
Cluster headache | 61.77 | 17.99 | 16 | 7461 | 514 | 31689353 |
Device malfunction | 61.56 | 17.99 | 34 | 7443 | 9232 | 31680635 |
Device issue | 56.00 | 17.99 | 31 | 7446 | 8453 | 31681414 |
Serotonin syndrome | 50.36 | 17.99 | 39 | 7438 | 18734 | 31671133 |
Throat tightness | 47.83 | 17.99 | 27 | 7450 | 7642 | 31682225 |
IIIrd nerve paresis | 44.89 | 17.99 | 9 | 7468 | 87 | 31689780 |
Accidental exposure to product | 42.48 | 17.99 | 29 | 7448 | 11466 | 31678401 |
Hyperhidrosis | 37.06 | 17.99 | 61 | 7416 | 67332 | 31622535 |
Injection site pain | 35.01 | 17.99 | 42 | 7435 | 34592 | 31655275 |
Application site pain | 32.28 | 17.99 | 13 | 7464 | 1736 | 31688131 |
Medication overuse headache | 31.38 | 17.99 | 7 | 7470 | 117 | 31689750 |
Myofascial pain syndrome | 29.54 | 17.99 | 8 | 7469 | 306 | 31689561 |
Drug ineffective | 27.55 | 17.99 | 173 | 7304 | 395400 | 31294467 |
Application site burn | 27.48 | 17.99 | 7 | 7470 | 210 | 31689657 |
Acute kidney injury | 27.48 | 17.99 | 16 | 7461 | 279698 | 31410169 |
Xanthelasma | 27.20 | 17.99 | 6 | 7471 | 95 | 31689772 |
Gastrointestinal tract irritation | 26.87 | 17.99 | 7 | 7470 | 230 | 31689637 |
Anophthalmos | 26.64 | 17.99 | 4 | 7473 | 4 | 31689863 |
Needle issue | 26.13 | 17.99 | 16 | 7461 | 5257 | 31684610 |
Congenital genital malformation male | 25.02 | 17.99 | 4 | 7473 | 8 | 31689859 |
Facial pain | 24.27 | 17.99 | 11 | 7466 | 1960 | 31687907 |
Burns second degree | 23.90 | 17.99 | 7 | 7470 | 357 | 31689510 |
Foetal malnutrition | 23.88 | 17.99 | 5 | 7472 | 61 | 31689806 |
Autonomic dysreflexia | 23.31 | 17.99 | 5 | 7472 | 69 | 31689798 |
Electrocardiogram ST segment elevation | 22.76 | 17.99 | 14 | 7463 | 4637 | 31685230 |
Foetal exposure during pregnancy | 22.45 | 17.99 | 37 | 7440 | 40839 | 31649028 |
Death | 21.96 | 17.99 | 32 | 7445 | 360537 | 31329330 |
Chest pain | 21.96 | 17.99 | 69 | 7408 | 116888 | 31572979 |
Capillaritis | 21.38 | 17.99 | 5 | 7472 | 104 | 31689763 |
Paraesthesia | 20.98 | 17.99 | 43 | 7434 | 56028 | 31633839 |
Muscle tightness | 20.56 | 17.99 | 13 | 7464 | 4516 | 31685351 |
Application site erythema | 20.42 | 17.99 | 10 | 7467 | 2119 | 31687748 |
Craniosynostosis | 19.85 | 17.99 | 6 | 7471 | 341 | 31689526 |
Aphasia | 19.85 | 17.99 | 24 | 7453 | 19907 | 31669960 |
Irritable bowel syndrome | 19.47 | 17.99 | 11 | 7466 | 3117 | 31686750 |
Tobacco abuse | 18.91 | 17.99 | 6 | 7471 | 401 | 31689466 |
Chest discomfort | 18.63 | 17.99 | 38 | 7439 | 49331 | 31640536 |
Anaemia | 18.53 | 17.99 | 14 | 7463 | 213508 | 31476359 |
Injection site haemorrhage | 18.32 | 17.99 | 16 | 7461 | 9069 | 31680798 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Product physical issue | 1336.42 | 12.29 | 329 | 39877 | 3385 | 70884853 |
Migraine | 1151.10 | 12.29 | 635 | 39571 | 71603 | 70816635 |
Application site erythema | 407.88 | 12.29 | 138 | 40068 | 4623 | 70883615 |
Product dose omission issue | 325.15 | 12.29 | 500 | 39706 | 216968 | 70671270 |
Application site burn | 286.92 | 12.29 | 71 | 40135 | 745 | 70887493 |
Application site pain | 238.87 | 12.29 | 91 | 40115 | 4311 | 70883927 |
Product quality issue | 233.56 | 12.29 | 169 | 40037 | 30392 | 70857846 |
Headache | 217.06 | 12.29 | 771 | 39435 | 579634 | 70308604 |
Application site discolouration | 195.39 | 12.29 | 51 | 40155 | 673 | 70887565 |
Application site paraesthesia | 182.68 | 12.29 | 32 | 40174 | 37 | 70888201 |
Device malfunction | 182.14 | 12.29 | 121 | 40085 | 18963 | 70869275 |
Arteriospasm coronary | 150.97 | 12.29 | 72 | 40134 | 5952 | 70882286 |
Accidental exposure to product | 144.68 | 12.29 | 123 | 40083 | 27928 | 70860310 |
Medication overuse headache | 132.73 | 12.29 | 38 | 40168 | 721 | 70887517 |
IIIrd nerve paresis | 118.60 | 12.29 | 26 | 40180 | 151 | 70888087 |
Throat tightness | 117.48 | 12.29 | 104 | 40102 | 24918 | 70863320 |
Colitis ischaemic | 112.15 | 12.29 | 80 | 40126 | 14057 | 70874181 |
Acute kidney injury | 110.81 | 12.29 | 66 | 40140 | 474558 | 70413680 |
Anxiety | 104.56 | 12.29 | 318 | 39888 | 220012 | 70668226 |
Application site pruritus | 102.49 | 12.29 | 47 | 40159 | 3554 | 70884684 |
Application site warmth | 101.09 | 12.29 | 23 | 40183 | 162 | 70888076 |
Application site irritation | 100.76 | 12.29 | 37 | 40169 | 1580 | 70886658 |
Device deployment issue | 98.68 | 12.29 | 43 | 40163 | 2881 | 70885357 |
Paraesthesia | 95.90 | 12.29 | 237 | 39969 | 145300 | 70742938 |
Death | 92.27 | 12.29 | 92 | 40114 | 509969 | 70378269 |
Application site urticaria | 89.67 | 12.29 | 22 | 40184 | 222 | 70888016 |
Application site rash | 89.48 | 12.29 | 36 | 40170 | 1973 | 70886265 |
Serotonin syndrome | 85.10 | 12.29 | 112 | 40094 | 42002 | 70846236 |
Reversible cerebral vasoconstriction syndrome | 82.60 | 12.29 | 37 | 40169 | 2648 | 70885590 |
Wrong technique in product usage process | 79.50 | 12.29 | 141 | 40065 | 68557 | 70819681 |
Device issue | 78.89 | 12.29 | 82 | 40124 | 23943 | 70864295 |
Anaemia | 73.78 | 12.29 | 72 | 40134 | 403351 | 70484887 |
Endometriosis | 73.02 | 12.29 | 36 | 40170 | 3200 | 70885038 |
Cluster headache | 72.14 | 12.29 | 25 | 40181 | 900 | 70887338 |
Application site swelling | 71.37 | 12.29 | 23 | 40183 | 659 | 70887579 |
Cerebral vasoconstriction | 70.18 | 12.29 | 27 | 40179 | 1313 | 70886925 |
Application site scar | 68.89 | 12.29 | 17 | 40189 | 176 | 70888062 |
Dizziness | 68.69 | 12.29 | 474 | 39732 | 463667 | 70424571 |
Depression | 66.88 | 12.29 | 256 | 39950 | 198718 | 70689520 |
Muscle twitching | 65.69 | 12.29 | 68 | 40138 | 19759 | 70868479 |
Chest discomfort | 65.10 | 12.29 | 186 | 40020 | 124195 | 70764043 |
Drug ineffective | 60.59 | 12.29 | 804 | 39402 | 938948 | 69949290 |
Cardiac failure | 59.79 | 12.29 | 6 | 40200 | 143535 | 70744703 |
Emotional distress | 58.89 | 12.29 | 88 | 40118 | 37100 | 70851138 |
Injection site pain | 58.77 | 12.29 | 173 | 40033 | 117446 | 70770792 |
Pituitary tumour benign | 57.19 | 12.29 | 28 | 40178 | 2451 | 70885787 |
Rheumatoid arthritis | 56.97 | 12.29 | 49 | 40157 | 291756 | 70596482 |
Post-traumatic neck syndrome | 56.93 | 12.29 | 26 | 40180 | 1947 | 70886291 |
Application site vesicles | 56.32 | 12.29 | 23 | 40183 | 1310 | 70886928 |
Incorrect route of product administration | 55.92 | 12.29 | 72 | 40134 | 26420 | 70861818 |
Hot flush | 53.82 | 12.29 | 99 | 40107 | 49485 | 70838753 |
Concussion | 53.74 | 12.29 | 42 | 40164 | 8467 | 70879771 |
Febrile neutropenia | 52.59 | 12.29 | 25 | 40181 | 204293 | 70683945 |
Cholecystitis chronic | 52.23 | 12.29 | 43 | 40163 | 9333 | 70878905 |
Coronary artery dissection | 51.76 | 12.29 | 20 | 40186 | 984 | 70887254 |
Hypoaesthesia | 50.97 | 12.29 | 197 | 40009 | 153542 | 70734696 |
Soft tissue injury | 50.65 | 12.29 | 23 | 40183 | 1699 | 70886539 |
Chest pain | 50.58 | 12.29 | 278 | 39928 | 250982 | 70637256 |
Pneumonia | 50.14 | 12.29 | 172 | 40034 | 596060 | 70292178 |
Nausea | 49.94 | 12.29 | 717 | 39489 | 851371 | 70036867 |
Drug specific antibody | 49.75 | 12.29 | 25 | 40181 | 2314 | 70885924 |
Hostility | 47.67 | 12.29 | 24 | 40182 | 2231 | 70886007 |
Muscle tightness | 47.61 | 12.29 | 45 | 40161 | 11717 | 70876521 |
Injection site haemorrhage | 47.15 | 12.29 | 65 | 40141 | 25462 | 70862776 |
Neutropenia | 46.84 | 12.29 | 46 | 40160 | 257110 | 70631128 |
Libido increased | 45.80 | 12.29 | 22 | 40184 | 1847 | 70886391 |
Sepsis | 45.40 | 12.29 | 43 | 40163 | 244502 | 70643736 |
Tension headache | 45.05 | 12.29 | 27 | 40179 | 3534 | 70884704 |
Renal infarct | 45.00 | 12.29 | 24 | 40182 | 2513 | 70885725 |
Application site exfoliation | 44.80 | 12.29 | 14 | 40192 | 362 | 70887876 |
Application site dryness | 44.67 | 12.29 | 12 | 40194 | 178 | 70888060 |
Sternal fracture | 43.85 | 12.29 | 23 | 40183 | 2328 | 70885910 |
Disease progression | 42.14 | 12.29 | 18 | 40188 | 156654 | 70731584 |
Product substitution issue | 41.74 | 12.29 | 52 | 40154 | 18461 | 70869777 |
Renal failure | 41.67 | 12.29 | 28 | 40178 | 189042 | 70699196 |
Infusion related reaction | 41.24 | 12.29 | 31 | 40175 | 197503 | 70690735 |
Device power source issue | 40.92 | 12.29 | 16 | 40190 | 813 | 70887425 |
Hyperkalaemia | 40.60 | 12.29 | 6 | 40200 | 106585 | 70781653 |
Interstitial lung disease | 39.63 | 12.29 | 6 | 40200 | 104679 | 70783559 |
Renal impairment | 39.58 | 12.29 | 16 | 40190 | 143921 | 70744317 |
Hypotension | 39.38 | 12.29 | 109 | 40097 | 404272 | 70483966 |
Injection site bruising | 38.86 | 12.29 | 74 | 40132 | 37958 | 70850280 |
Pancytopenia | 38.10 | 12.29 | 19 | 40187 | 151088 | 70737150 |
Treatment failure | 38.07 | 12.29 | 17 | 40189 | 144125 | 70744113 |
Angle closure glaucoma | 37.59 | 12.29 | 22 | 40184 | 2757 | 70885481 |
Platelet count decreased | 37.16 | 12.29 | 28 | 40178 | 178194 | 70710044 |
Pericarditis | 36.72 | 12.29 | 3 | 40203 | 84702 | 70803536 |
Hyponatraemia | 36.23 | 12.29 | 23 | 40183 | 160064 | 70728174 |
Feeling abnormal | 36.01 | 12.29 | 168 | 40038 | 142151 | 70746087 |
Clonus | 35.45 | 12.29 | 29 | 40177 | 6239 | 70881999 |
Multiple organ dysfunction syndrome | 35.25 | 12.29 | 9 | 40197 | 108506 | 70779732 |
Vision blurred | 35.04 | 12.29 | 126 | 40080 | 94858 | 70793380 |
Thrombocytopenia | 34.78 | 12.29 | 51 | 40155 | 239059 | 70649179 |
Atrial fibrillation | 34.69 | 12.29 | 32 | 40174 | 184316 | 70703922 |
Application site inflammation | 34.09 | 12.29 | 12 | 40194 | 453 | 70887785 |
Suicidal ideation | 33.45 | 12.29 | 101 | 40105 | 69495 | 70818743 |
Glossodynia | 32.64 | 12.29 | 5 | 40201 | 86482 | 70801756 |
Photophobia | 32.23 | 12.29 | 46 | 40160 | 18604 | 70869634 |
Palpitations | 31.98 | 12.29 | 136 | 40070 | 110617 | 70777621 |
Septic shock | 31.65 | 12.29 | 12 | 40194 | 112246 | 70775992 |
Lower respiratory tract infection | 31.49 | 12.29 | 12 | 40194 | 111901 | 70776337 |
Expired product administered | 30.78 | 12.29 | 27 | 40179 | 6386 | 70881852 |
Drug hypersensitivity | 30.78 | 12.29 | 254 | 39952 | 262205 | 70626033 |
Plasma cell myeloma | 30.63 | 12.29 | 3 | 40203 | 73198 | 70815040 |
Wound | 30.55 | 12.29 | 9 | 40197 | 98723 | 70789515 |
Nightmare | 30.28 | 12.29 | 49 | 40157 | 22107 | 70866131 |
Application site scab | 30.09 | 12.29 | 9 | 40197 | 200 | 70888038 |
Gastrointestinal haemorrhage | 29.40 | 12.29 | 21 | 40185 | 137387 | 70750851 |
Blood creatinine increased | 29.13 | 12.29 | 23 | 40183 | 142978 | 70745260 |
Injury | 28.86 | 12.29 | 92 | 40114 | 65153 | 70823085 |
Pleural effusion | 28.83 | 12.29 | 20 | 40186 | 132844 | 70755394 |
Pharyngeal swelling | 28.66 | 12.29 | 26 | 40180 | 6427 | 70881811 |
Application site bruise | 28.36 | 12.29 | 9 | 40197 | 245 | 70887993 |
Hyperprolactinaemia | 28.34 | 12.29 | 22 | 40184 | 4391 | 70883847 |
Secondary adrenocortical insufficiency | 28.23 | 12.29 | 18 | 40188 | 2629 | 70885609 |
Malignant neoplasm progression | 28.23 | 12.29 | 17 | 40189 | 121722 | 70766516 |
Hyperhidrosis | 28.07 | 12.29 | 148 | 40058 | 131438 | 70756800 |
Hepatic function abnormal | 27.90 | 12.29 | 3 | 40203 | 67993 | 70820245 |
Haemoglobin decreased | 27.69 | 12.29 | 46 | 40160 | 205113 | 70683125 |
Subclavian artery thrombosis | 27.64 | 12.29 | 6 | 40200 | 33 | 70888205 |
Transient global amnesia | 26.93 | 12.29 | 12 | 40194 | 848 | 70887390 |
Pyrexia | 26.78 | 12.29 | 218 | 39988 | 606734 | 70281504 |
Product adhesion issue | 26.51 | 12.29 | 17 | 40189 | 2507 | 70885731 |
Off label use | 26.31 | 12.29 | 282 | 39924 | 742778 | 70145460 |
Personality disorder | 25.91 | 12.29 | 23 | 40183 | 5525 | 70882713 |
Application site reaction | 25.60 | 12.29 | 11 | 40195 | 712 | 70887526 |
Pain | 25.58 | 12.29 | 499 | 39707 | 628317 | 70259921 |
Vasospasm | 25.40 | 12.29 | 12 | 40194 | 971 | 70887267 |
Poor quality sleep | 25.13 | 12.29 | 43 | 40163 | 20306 | 70867932 |
Electrocardiogram ST segment elevation | 25.04 | 12.29 | 26 | 40180 | 7578 | 70880660 |
Application site discomfort | 25.02 | 12.29 | 9 | 40197 | 362 | 70887876 |
Somnambulism | 24.96 | 12.29 | 22 | 40184 | 5238 | 70883000 |
Dysgeusia | 24.88 | 12.29 | 73 | 40133 | 49429 | 70838809 |
Product leakage | 24.78 | 12.29 | 11 | 40195 | 770 | 70887468 |
Middle insomnia | 24.78 | 12.29 | 35 | 40171 | 14018 | 70874220 |
Respiratory failure | 24.52 | 12.29 | 36 | 40170 | 168699 | 70719539 |
Therapeutic response unexpected | 24.48 | 12.29 | 40 | 40166 | 18191 | 70870047 |
Cerebral venous thrombosis | 24.12 | 12.29 | 16 | 40190 | 2499 | 70885739 |
Incorrect dose administered by device | 24.02 | 12.29 | 20 | 40186 | 4409 | 70883829 |
Device leakage | 24.01 | 12.29 | 28 | 40178 | 9280 | 70878958 |
Memory impairment | 23.89 | 12.29 | 110 | 40096 | 92531 | 70795707 |
Temperature intolerance | 23.78 | 12.29 | 27 | 40179 | 8696 | 70879542 |
Cardiac failure congestive | 23.77 | 12.29 | 25 | 40181 | 135432 | 70752806 |
Migraine without aura | 23.75 | 12.29 | 8 | 40198 | 264 | 70887974 |
Muscle spasms | 23.68 | 12.29 | 159 | 40047 | 153887 | 70734351 |
Infection | 23.46 | 12.29 | 53 | 40153 | 210732 | 70677506 |
Vasoconstriction | 23.18 | 12.29 | 10 | 40196 | 654 | 70887584 |
Phonophobia | 22.76 | 12.29 | 9 | 40197 | 471 | 70887767 |
Product complaint | 22.37 | 12.29 | 31 | 40175 | 12200 | 70876038 |
Gastrooesophageal reflux disease | 22.06 | 12.29 | 106 | 40100 | 90733 | 70797505 |
Renal tubular acidosis | 22.00 | 12.29 | 17 | 40189 | 3369 | 70884869 |
Insomnia | 21.99 | 12.29 | 204 | 40002 | 217602 | 70670636 |
Drug dependence | 21.67 | 12.29 | 58 | 40148 | 37263 | 70850975 |
Gallbladder disorder | 21.31 | 12.29 | 37 | 40169 | 17675 | 70870563 |
Systemic lupus erythematosus | 21.25 | 12.29 | 16 | 40190 | 101886 | 70786352 |
Tremor | 21.20 | 12.29 | 156 | 40050 | 155468 | 70732770 |
Burning sensation | 21.10 | 12.29 | 72 | 40134 | 52798 | 70835440 |
Neck pain | 20.92 | 12.29 | 84 | 40122 | 66573 | 70821665 |
Head discomfort | 20.87 | 12.29 | 31 | 40175 | 12992 | 70875246 |
Arthropathy | 20.85 | 12.29 | 33 | 40173 | 150024 | 70738214 |
Myofascial pain syndrome | 20.83 | 12.29 | 13 | 40193 | 1829 | 70886409 |
Irritability | 20.79 | 12.29 | 58 | 40148 | 38167 | 70850071 |
General physical health deterioration | 20.51 | 12.29 | 67 | 40139 | 235964 | 70652274 |
Pharyngeal oedema | 20.49 | 12.29 | 34 | 40172 | 15662 | 70872576 |
Post-traumatic stress disorder | 20.05 | 12.29 | 18 | 40188 | 4389 | 70883849 |
Pre-existing condition improved | 19.98 | 12.29 | 19 | 40187 | 4983 | 70883255 |
Decreased appetite | 19.85 | 12.29 | 97 | 40109 | 304683 | 70583555 |
Migraine with aura | 19.83 | 12.29 | 14 | 40192 | 2418 | 70885820 |
Basilar migraine | 19.67 | 12.29 | 5 | 40201 | 59 | 70888179 |
Paraesthesia oral | 19.59 | 12.29 | 33 | 40173 | 15384 | 70872854 |
Application site papules | 19.59 | 12.29 | 5 | 40201 | 60 | 70888178 |
Flushing | 19.32 | 12.29 | 95 | 40111 | 82077 | 70806161 |
Burns second degree | 19.31 | 12.29 | 10 | 40196 | 986 | 70887252 |
Contraindicated product administered | 19.28 | 12.29 | 29 | 40177 | 134583 | 70753655 |
Impaired healing | 19.28 | 12.29 | 9 | 40197 | 74365 | 70813873 |
Aphasia | 19.14 | 12.29 | 61 | 40145 | 43188 | 70845050 |
International normalised ratio increased | 19.09 | 12.29 | 11 | 40195 | 80715 | 70807523 |
Withdrawal syndrome | 19.02 | 12.29 | 43 | 40163 | 24861 | 70863377 |
Complement factor C4 decreased | 19.01 | 12.29 | 7 | 40199 | 301 | 70887937 |
Xanthelasma | 18.89 | 12.29 | 6 | 40200 | 164 | 70888074 |
Hyperreflexia | 18.56 | 12.29 | 22 | 40184 | 7420 | 70880818 |
Loss of consciousness | 18.39 | 12.29 | 151 | 40055 | 155565 | 70732673 |
Facial pain | 18.35 | 12.29 | 23 | 40183 | 8213 | 70880025 |
Visual impairment | 18.31 | 12.29 | 92 | 40114 | 80158 | 70808080 |
Dependence | 18.20 | 12.29 | 13 | 40193 | 2287 | 70885951 |
Blood pressure systolic increased | 18.11 | 12.29 | 5 | 40201 | 57254 | 70830984 |
Epistaxis | 17.93 | 12.29 | 19 | 40187 | 102608 | 70785630 |
Diarrhoea | 17.79 | 12.29 | 325 | 39881 | 783016 | 70105222 |
Meningitis aseptic | 17.72 | 12.29 | 20 | 40186 | 6399 | 70881839 |
Ovarian neoplasm | 17.72 | 12.29 | 8 | 40198 | 583 | 70887655 |
Biliary dyskinesia | 17.71 | 12.29 | 13 | 40193 | 2386 | 70885852 |
Complement factor C3 decreased | 17.71 | 12.29 | 7 | 40199 | 366 | 70887872 |
Blood bilirubin increased | 17.57 | 12.29 | 6 | 40200 | 59895 | 70828343 |
Transverse sinus thrombosis | 17.33 | 12.29 | 8 | 40198 | 614 | 70887624 |
Application site erosion | 17.23 | 12.29 | 6 | 40200 | 219 | 70888019 |
Hyperacusis | 17.19 | 12.29 | 12 | 40194 | 2036 | 70886202 |
Sunburn | 17.07 | 12.29 | 15 | 40191 | 3556 | 70884682 |
Peripheral coldness | 17.07 | 12.29 | 30 | 40176 | 14470 | 70873768 |
Burns third degree | 17.00 | 12.29 | 7 | 40199 | 407 | 70887831 |
Injection site erythema | 16.92 | 12.29 | 84 | 40122 | 72840 | 70815398 |
Therapeutic product effect incomplete | 16.80 | 12.29 | 121 | 40085 | 119761 | 70768477 |
Teratogenicity | 16.78 | 12.29 | 6 | 40200 | 237 | 70888001 |
Multiple sclerosis relapse | 16.66 | 12.29 | 58 | 40148 | 42959 | 70845279 |
Lactic acidosis | 16.65 | 12.29 | 8 | 40198 | 65016 | 70823222 |
Body temperature increased | 16.56 | 12.29 | 55 | 40151 | 39779 | 70848459 |
Superior sagittal sinus thrombosis | 16.42 | 12.29 | 9 | 40197 | 995 | 70887243 |
Hepatic enzyme increased | 16.25 | 12.29 | 41 | 40165 | 156949 | 70731289 |
Hormone level abnormal | 16.23 | 12.29 | 11 | 40195 | 1779 | 70886459 |
Injection site laceration | 16.12 | 12.29 | 5 | 40201 | 126 | 70888112 |
Eyelid ptosis | 16.12 | 12.29 | 24 | 40182 | 10078 | 70878160 |
Bone marrow failure | 16.04 | 12.29 | 4 | 40202 | 49006 | 70839232 |
Toxicity to various agents | 16.03 | 12.29 | 139 | 40067 | 382033 | 70506205 |
Haematuria | 16.01 | 12.29 | 8 | 40198 | 63565 | 70824673 |
Vertigo | 15.86 | 12.29 | 74 | 40132 | 62569 | 70825669 |
Oxygen saturation decreased | 15.80 | 12.29 | 26 | 40180 | 116403 | 70771835 |
Meningoradiculitis | 15.42 | 12.29 | 5 | 40201 | 146 | 70888092 |
Pancreatic failure | 15.35 | 12.29 | 10 | 40196 | 1514 | 70886724 |
Gallbladder injury | 15.26 | 12.29 | 9 | 40197 | 1143 | 70887095 |
Swollen tongue | 15.26 | 12.29 | 51 | 40155 | 36995 | 70851243 |
Post viral fatigue syndrome | 15.19 | 12.29 | 6 | 40200 | 313 | 70887925 |
Joint swelling | 15.12 | 12.29 | 83 | 40123 | 253128 | 70635110 |
Tinnitus | 15.08 | 12.29 | 50 | 40156 | 36126 | 70852112 |
Large intestinal ulcer haemorrhage | 15.07 | 12.29 | 6 | 40200 | 320 | 70887918 |
Cerebral venous sinus thrombosis | 14.98 | 12.29 | 11 | 40195 | 2020 | 70886218 |
Gastrointestinal tract irritation | 14.97 | 12.29 | 7 | 40199 | 553 | 70887685 |
Aspartate aminotransferase increased | 14.89 | 12.29 | 31 | 40175 | 126947 | 70761291 |
Hypoglycaemia | 14.84 | 12.29 | 19 | 40187 | 94345 | 70793893 |
Swelling face | 14.83 | 12.29 | 73 | 40133 | 63091 | 70825147 |
Torsade de pointes | 14.65 | 12.29 | 32 | 40174 | 18084 | 70870154 |
Pericardial effusion | 14.49 | 12.29 | 3 | 40203 | 41773 | 70846465 |
Deep vein thrombosis | 14.38 | 12.29 | 110 | 40096 | 110932 | 70777306 |
Incorrect disposal of product | 14.31 | 12.29 | 8 | 40198 | 919 | 70887319 |
Cardio-respiratory arrest | 14.11 | 12.29 | 22 | 40184 | 100655 | 70787583 |
Haemorrhage | 14.11 | 12.29 | 16 | 40190 | 83799 | 70804439 |
Peripheral nerve injury | 13.75 | 12.29 | 7 | 40199 | 666 | 70887572 |
Stomatitis | 13.74 | 12.29 | 33 | 40173 | 128478 | 70759760 |
Injection site urticaria | 13.60 | 12.29 | 24 | 40182 | 11614 | 70876624 |
Incorrect product administration duration | 13.53 | 12.29 | 23 | 40183 | 10801 | 70877437 |
Injection site injury | 13.50 | 12.29 | 7 | 40199 | 692 | 70887546 |
Device difficult to use | 13.49 | 12.29 | 23 | 40183 | 10826 | 70877412 |
Cytomegalovirus infection | 13.49 | 12.29 | 3 | 40203 | 39755 | 70848483 |
Panic attack | 13.47 | 12.29 | 35 | 40171 | 22084 | 70866154 |
Bradycardia | 13.32 | 12.29 | 32 | 40174 | 124583 | 70763655 |
Inflammation | 13.26 | 12.29 | 15 | 40191 | 78650 | 70809588 |
Drug effect less than expected | 13.17 | 12.29 | 8 | 40198 | 1072 | 70887166 |
Major depression | 13.16 | 12.29 | 20 | 40186 | 8554 | 70879684 |
Product dispensing error | 13.05 | 12.29 | 24 | 40182 | 11984 | 70876254 |
Neutrophil count decreased | 12.96 | 12.29 | 17 | 40189 | 83539 | 70804699 |
Choking sensation | 12.95 | 12.29 | 13 | 40193 | 3642 | 70884596 |
Lichen planus | 12.83 | 12.29 | 11 | 40195 | 2524 | 70885714 |
Somnolence | 12.74 | 12.29 | 182 | 40024 | 215424 | 70672814 |
Alanine aminotransferase increased | 12.71 | 12.29 | 42 | 40164 | 147438 | 70740800 |
Trismus | 12.61 | 12.29 | 15 | 40191 | 5076 | 70883162 |
Neoplasm progression | 12.47 | 12.29 | 5 | 40201 | 45223 | 70843015 |
Product use issue | 12.45 | 12.29 | 56 | 40150 | 179881 | 70708357 |
Hyperglycaemia | 12.43 | 12.29 | 11 | 40195 | 64661 | 70823577 |
Depressive symptom | 12.40 | 12.29 | 15 | 40191 | 5166 | 70883072 |
Capillaritis | 12.39 | 12.29 | 5 | 40201 | 276 | 70887962 |
Eye pain | 12.36 | 12.29 | 45 | 40161 | 34057 | 70854181 |
None
Source | Code | Description |
---|---|---|
ATC | N02CC01 | NERVOUS SYSTEM ANALGESICS ANTIMIGRAINE PREPARATIONS Selective serotonin (5HT1) agonists |
CHEBI has role | CHEBI:35941 | serotonin agonists |
FDA MoA | N0000175763 | Serotonin 1b Receptor Agonists |
FDA MoA | N0000175764 | Serotonin 1d Receptor Agonists |
FDA EPC | N0000175765 | Serotonin-1b and Serotonin-1d Receptor Agonist |
MeSH PA | D002317 | Cardiovascular Agents |
MeSH PA | D018377 | Neurotransmitter Agents |
MeSH PA | D058825 | Serotonin 5-HT1 Receptor Agonists |
MeSH PA | D018490 | Serotonin Agents |
MeSH PA | D017366 | Serotonin Receptor Agonists |
MeSH PA | D014662 | Vasoconstrictor Agents |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Migraine | indication | 37796009 | DOID:6364 |
Cluster headache syndrome | indication | 193031009 | |
Tachyarrhythmia | contraindication | 6285003 | |
Alcoholism | contraindication | 7200002 | |
Hypercholesterolemia | contraindication | 13644009 | |
Myocardial infarction | contraindication | 22298006 | DOID:5844 |
Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
Gastrointestinal ulcer | contraindication | 40845000 | |
Body fluid retention | contraindication | 43498006 | |
Chronic heart failure | contraindication | 48447003 | |
Disorder of cardiovascular system | contraindication | 49601007 | DOID:1287 |
Hemiplegic migraine | contraindication | 59292006 | |
Hepatic failure | contraindication | 59927004 | |
Blood coagulation disorder | contraindication | 64779008 | DOID:1247 |
Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
Gastrointestinal hemorrhage | contraindication | 74474003 | |
Vascular insufficiency of intestine | contraindication | 82196007 | |
Epilepsy | contraindication | 84757009 | DOID:1826 |
Prinzmetal angina | contraindication | 87343002 | |
Kidney disease | contraindication | 90708001 | DOID:557 |
Liver function tests abnormal | contraindication | 166603001 | |
Angina pectoris | contraindication | 194828000 | |
Cerebrovascular accident | contraindication | 230690007 | |
Coronary artery bypass graft | contraindication | 232717009 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Transient ischemic attack | contraindication | 266257000 | DOID:224 |
Esophageal dysmotility | contraindication | 266434009 | DOID:9192 |
Edema | contraindication | 267038008 | |
Anemia | contraindication | 271737000 | DOID:2355 |
Cerebral ischemia | contraindication | 287731003 | |
Pregnancy, function | contraindication | 289908002 | |
Thromboembolic disorder | contraindication | 371039008 | |
Serotonin syndrome | contraindication | 371089000 | |
Cardiovascular event risk | contraindication | 395112001 | |
Peripheral vascular disease | contraindication | 400047006 | |
Disorder of coronary artery | contraindication | 414024009 | |
Myocardial ischemia | contraindication | 414795007 | DOID:3393 |
Obesity | contraindication | 414916001 | DOID:9970 |
Hypertensive urgency | contraindication | 443482000 | |
Smokes tobacco daily | contraindication | 449868002 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 11.23 | acidic |
pKa2 | 13.42 | acidic |
pKa3 | 8.28 | Basic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
EQ 11MG BASE | ONZETRA XSAIL | CURRAX | N206099 | Jan. 27, 2016 | RX | POWDER | NASAL | 8327844 | Oct. 3, 2023 | METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY |
EQ 11MG BASE | ONZETRA XSAIL | CURRAX | N206099 | Jan. 27, 2016 | RX | POWDER | NASAL | 7975690 | Aug. 18, 2025 | METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY |
EQ 11MG BASE | ONZETRA XSAIL | CURRAX | N206099 | Jan. 27, 2016 | RX | POWDER | NASAL | 8590530 | Sept. 15, 2025 | METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY |
500MG;EQ 85MG BASE | TREXIMET | CURRAX | N021926 | April 15, 2008 | RX | TABLET | ORAL | 7332183 | Oct. 2, 2025 | TREATMENT OF MIGRAINE |
60MG;EQ 10MG BASE | TREXIMET | CURRAX | N021926 | May 14, 2015 | DISCN | TABLET | ORAL | 7332183 | Oct. 2, 2025 | ACUTE TREATMENT OF MIGRAINE |
10MG/SPRAY | TOSYMRA | UPSHER SMITH LABS | N210884 | Jan. 25, 2019 | RX | SPRAY | NASAL | 8440631 | May 9, 2026 | ACUTE TREATMENT OF MIGRAINE |
EQ 11MG BASE | ONZETRA XSAIL | CURRAX | N206099 | Jan. 27, 2016 | RX | POWDER | NASAL | 10124132 | March 6, 2027 | ACUTE TREATMENT OF MIGRAINE |
EQ 11MG BASE | ONZETRA XSAIL | CURRAX | N206099 | Jan. 27, 2016 | RX | POWDER | NASAL | 10124132 | March 6, 2027 | ACUTE TREATMENT OF MIGRAINE BY DELIVERING A POWDERED SUBSTANCE COMPRISING SUMATRIPTAN VIA A BREATH-POWERED DELIVERY DEVICE |
EQ 11MG BASE | ONZETRA XSAIL | CURRAX | N206099 | Jan. 27, 2016 | RX | POWDER | NASAL | 10124132 | March 6, 2027 | TREATMENT OF MIGRAINE VIA DELIVERY OF SUMATRIPTAN VIA THE NASAL CAVITY |
EQ 6.5MG BASE/4HR | ZECUITY | TEVA BRANDED PHARM | N202278 | Jan. 17, 2013 | DISCN | SYSTEM | IONTOPHORESIS | 7973058 | April 12, 2027 | METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF |
EQ 6.5MG BASE/4HR | ZECUITY | TEVA BRANDED PHARM | N202278 | Jan. 17, 2013 | DISCN | SYSTEM | IONTOPHORESIS | 8155737 | April 12, 2027 | METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF |
EQ 6.5MG BASE/4HR | ZECUITY | TEVA BRANDED PHARM | N202278 | Jan. 17, 2013 | DISCN | SYSTEM | IONTOPHORESIS | 8470853 | April 12, 2027 | METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF |
EQ 6.5MG BASE/4HR | ZECUITY | TEVA BRANDED PHARM | N202278 | Jan. 17, 2013 | DISCN | SYSTEM | IONTOPHORESIS | 9427578 | April 12, 2027 | METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF |
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | ALSUMA | MERIDIAN MEDCL | N022377 | June 29, 2010 | DISCN | INJECTABLE | SUBCUTANEOUS | 7811254 | Aug. 26, 2027 | ACUTE TREATMENT OF MIGRAINE ATTACKS, WITH OR WITHOUT AURA, AND THE TREATMENT OF CLUSTER HEADACHE EPISODES |
EQ 11MG BASE | ONZETRA XSAIL | CURRAX | N206099 | Jan. 27, 2016 | RX | POWDER | NASAL | 8875704 | April 7, 2028 | METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY |
EQ 6.5MG BASE/4HR | ZECUITY | TEVA BRANDED PHARM | N202278 | Jan. 17, 2013 | DISCN | SYSTEM | IONTOPHORESIS | 8366600 | April 21, 2029 | METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF, USING A FLOWABLE HYDROGEL FORMULATION |
EQ 11MG BASE | ONZETRA XSAIL | CURRAX | N206099 | Jan. 27, 2016 | RX | POWDER | NASAL | 10076615 | July 30, 2029 | ACUTE TREATMENT OF MIGRAINE BY DELIVERING A POWDERED SUBSTANCE COMPRISING SUMATRIPTAN VIA A BREATH-POWERED DELIVERY DEVICE |
EQ 11MG BASE | ONZETRA XSAIL | CURRAX | N206099 | Jan. 27, 2016 | RX | POWDER | NASAL | 10076615 | July 30, 2029 | METHOD OF DELIVERING SUMATRIPTAN TO A NASAL CAVITY |
EQ 11MG BASE | ONZETRA XSAIL | CURRAX | N206099 | Jan. 27, 2016 | RX | POWDER | NASAL | 10076615 | July 30, 2029 | TREATMENT OF MIGRAINE VIA DELIVERY OF SUMATRIPTAN VIA THE NASAL CAVITY |
10MG/SPRAY | TOSYMRA | UPSHER SMITH LABS | N210884 | Jan. 25, 2019 | RX | SPRAY | NASAL | 10603305 | June 16, 2030 | ACUTE TREATMENT OF MIGRAINE |
10MG/SPRAY | TOSYMRA | UPSHER SMITH LABS | N210884 | Jan. 25, 2019 | RX | SPRAY | NASAL | 11337962 | June 16, 2030 | ACUTE TREATMENT OF MIGRAINE |
10MG/SPRAY | TOSYMRA | UPSHER SMITH LABS | N210884 | Jan. 25, 2019 | RX | SPRAY | NASAL | 9610280 | June 16, 2030 | ACUTE TREATMENT OF MIGRAINE |
10MG/SPRAY | TOSYMRA | UPSHER SMITH LABS | N210884 | Jan. 25, 2019 | RX | SPRAY | NASAL | 9974770 | June 16, 2030 | ACUTE TREATMENT OF MIGRAINE |
EQ 11MG BASE | ONZETRA XSAIL | CURRAX | N206099 | Jan. 27, 2016 | RX | POWDER | NASAL | 9649456 | Oct. 21, 2030 | ACUTE TREATMENT OF MIGRAINE |
EQ 11MG BASE | ONZETRA XSAIL | CURRAX | N206099 | Jan. 27, 2016 | RX | POWDER | NASAL | 9649456 | Oct. 21, 2030 | ACUTE TREATMENT OF MIGRAINE BY DELIVERING A POWDERED SUBSTANCE COMPRISING SUMATRIPTAN VIA A BREATH-POWERED DELIVERY DEVICE |
EQ 11MG BASE | ONZETRA XSAIL | CURRAX | N206099 | Jan. 27, 2016 | RX | POWDER | NASAL | 9649456 | Oct. 21, 2030 | TREATMENT OF MIGRAINE VIA DELIVERY OF SUMATRIPTAN VIA THE NASAL CAVITY |
EQ 6.5MG BASE/4HR | ZECUITY | TEVA BRANDED PHARM | N202278 | Jan. 17, 2013 | DISCN | SYSTEM | IONTOPHORESIS | 8983594 | Nov. 19, 2030 | METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF |
10MG/SPRAY | TOSYMRA | UPSHER SMITH LABS | N210884 | Jan. 25, 2019 | RX | SPRAY | NASAL | 9211282 | July 19, 2031 | ACUTE TREATMENT OF MIGRAINE |
EQ 6.5MG BASE/4HR | ZECUITY | TEVA BRANDED PHARM | N202278 | Jan. 17, 2013 | DISCN | SYSTEM | IONTOPHORESIS | 9327114 | Oct. 8, 2032 | METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF |
EQ 11MG BASE | ONZETRA XSAIL | CURRAX | N206099 | Jan. 27, 2016 | RX | POWDER | NASAL | 10478574 | Nov. 4, 2033 | METHOD OF DELIVERING SUMATRIPTAN TO A NASAL CAVITY |
EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML) | ZEMBRACE SYMTOUCH | UPSHER SMITH LABS | N208223 | Jan. 28, 2016 | RX | SOLUTION | SUBCUTANEOUS | 10537554 | Jan. 29, 2036 | TREATMENT OF MIGRAINE |
EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML) | ZEMBRACE SYMTOUCH | UPSHER SMITH LABS | N208223 | Jan. 28, 2016 | RX | SOLUTION | SUBCUTANEOUS | 11364224 | Jan. 29, 2036 | TREATMENT OF MIGRAINE |
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
5-hydroxytryptamine receptor 1D | GPCR | AGONIST | Ki | 8.92 | CHEMBL | CHEMBL | |||
5-hydroxytryptamine receptor 1B | GPCR | AGONIST | Ki | 8.26 | CHEMBL | CHEMBL | |||
5-hydroxytryptamine receptor 2C | GPCR | IC50 | 8.14 | CHEMBL | |||||
5-hydroxytryptamine receptor 6 | GPCR | ANTAGONIST | Ki | 5.60 | IUPHAR | ||||
5-hydroxytryptamine receptor 7 | GPCR | ANTAGONIST | Ki | 6 | IUPHAR | ||||
5-hydroxytryptamine receptor 3A | Ion channel | IC50 | 8.03 | CHEMBL | |||||
5-hydroxytryptamine receptor 5A | GPCR | IC50 | 6.30 | CHEMBL | |||||
5-hydroxytryptamine receptor 1F | GPCR | Ki | 7.59 | CHEMBL | |||||
5-hydroxytryptamine receptor 1E | GPCR | IC50 | 5.26 | CHEMBL | |||||
Multidrug and toxin extrusion protein 1 | Transporter | IC50 | 5.17 | CHEMBL | |||||
5-hydroxytryptamine receptor 1A | GPCR | Ki | 6.64 | CHEMBL | |||||
5-hydroxytryptamine receptor 2A | GPCR | Ki | 6.42 | CHEMBL | |||||
5-hydroxytryptamine receptor 1B | GPCR | Ki | 7.64 | CHEMBL | |||||
5-hydroxytryptamine receptor 1A | GPCR | IC50 | 6.19 | CHEMBL | |||||
5-hydroxytryptamine receptor 7 | GPCR | ANTAGONIST | Ki | 6.60 | IUPHAR | ||||
5-hydroxytryptamine receptor 1D | GPCR | IC50 | 7.70 | CHEMBL | |||||
5-hydroxytryptamine receptor 1A | GPCR | IC50 | 6.35 | CHEMBL | |||||
5-hydroxytryptamine receptor 1D | GPCR | IC50 | 7.21 | CHEMBL | |||||
5-hydroxytryptamine receptor 6 | GPCR | ANTAGONIST | Ki | 5.20 | IUPHAR | ||||
5-hydroxytryptamine receptor 1B | GPCR | Ki | 8.19 | CHEMBL | |||||
5-hydroxytryptamine 1D receptor | Unclassified | IC50 | 7.23 | CHEMBL | |||||
5-hydroxytryptamine receptor 5A | GPCR | AGONIST | Ki | 4.80 | IUPHAR |
ID | Source |
---|---|
4021050 | VUID |
N0000148514 | NUI |
D00451 | KEGG_DRUG |
103628-48-4 | SECONDARY_CAS_RN |
4020790 | VANDF |
4021050 | VANDF |
C0075632 | UMLSCUI |
CHEBI:10650 | CHEBI |
CHEMBL128 | ChEMBL_ID |
DB00669 | DRUGBANK_ID |
CHEMBL1201150 | ChEMBL_ID |
D018170 | MESH_DESCRIPTOR_UI |
5358 | PUBCHEM_CID |
54 | IUPHAR_LIGAND_ID |
6125 | INN_ID |
8R78F6L9VO | UNII |
37418 | RXNORM |
158892 | MMSL |
166806 | MMSL |
25268 | MMSL |
31925 | MMSL |
5536 | MMSL |
d03160 | MMSL |
004044 | NDDF |
004045 | NDDF |
322822007 | SNOMEDCT_US |
395892000 | SNOMEDCT_US |
96215002 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Sumatriptan | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-2013 | INJECTION | 4 mg | SUBCUTANEOUS | ANDA | 28 sections |
Sumatriptan | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-2014 | INJECTION | 6 mg | SUBCUTANEOUS | ANDA | 28 sections |
SUMATRIPTAN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9638 | INJECTION | 6 mg | SUBCUTANEOUS | ANDA | 27 sections |
IMITREX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0173-0478 | INJECTION | 6 mg | SUBCUTANEOUS | NDA | 28 sections |
IMITREX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0173-0478 | INJECTION | 6 mg | SUBCUTANEOUS | NDA | 28 sections |
IMITREX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0173-0479 | INJECTION | 6 mg | SUBCUTANEOUS | NDA | 28 sections |
IMITREX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0173-0479 | INJECTION | 6 mg | SUBCUTANEOUS | NDA | 28 sections |
IMITREX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0173-0523 | SPRAY | 20 mg | NASAL | NDA | 27 sections |
IMITREX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0173-0523 | SPRAY | 20 mg | NASAL | NDA | 27 sections |
IMITREX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0173-0524 | SPRAY | 5 mg | NASAL | NDA | 27 sections |
IMITREX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0173-0524 | SPRAY | 5 mg | NASAL | NDA | 27 sections |
IMITREX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0173-0735 | TABLET, FILM COATED | 25 mg | ORAL | NDA | 27 sections |
IMITREX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0173-0735 | TABLET, FILM COATED | 25 mg | ORAL | NDA | 27 sections |
IMITREX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0173-0736 | TABLET, FILM COATED | 50 mg | ORAL | NDA | 27 sections |
IMITREX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0173-0736 | TABLET, FILM COATED | 50 mg | ORAL | NDA | 27 sections |
IMITREX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0173-0737 | TABLET, FILM COATED | 100 mg | ORAL | NDA | 27 sections |
IMITREX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0173-0737 | TABLET, FILM COATED | 100 mg | ORAL | NDA | 27 sections |
IMITREX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0173-0739 | INJECTION | 4 mg | SUBCUTANEOUS | NDA | 28 sections |
IMITREX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0173-0739 | INJECTION | 4 mg | SUBCUTANEOUS | NDA | 28 sections |
ZEMBRACE SYMTOUCH | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0245-0809 | INJECTION, SOLUTION | 3 mg | SUBCUTANEOUS | NDA | 31 sections |
TOSYMRA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0245-0812 | SPRAY | 10 mg | NASAL | NDA | 31 sections |
Sumatriptan Succinate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-5630 | TABLET, FILM COATED | 25 mg | ORAL | ANDA | 28 sections |
Sumatriptan Succinate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-5630 | TABLET, FILM COATED | 25 mg | ORAL | ANDA | 28 sections |
Sumatriptan Succinate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-5631 | TABLET, FILM COATED | 50 mg | ORAL | ANDA | 28 sections |
Sumatriptan Succinate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-5631 | TABLET, FILM COATED | 50 mg | ORAL | ANDA | 28 sections |
Sumatriptan Succinate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-5632 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 28 sections |
Sumatriptan Succinate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-5632 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 28 sections |
Sumatriptan | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1818 | SPRAY | 5 mg | NASAL | ANDA | 28 sections |
Sumatriptan | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1859 | SPRAY | 20 mg | NASAL | ANDA | 28 sections |
Sumatriptan Succinate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-300 | TABLET, FILM COATED | 100 mg | ORAL | NDA | 13 sections |